SKXJF SANKYO CO LTD
- 9.934
- 0.0000.00%
SANKYO CO LTD News
SANKYO CO LTD To Go Ex-Dividend On September 27th, 2024 With 0.352 USD Dividend Per Share
Daiichi Sankyo Buys Back Shares Worth Over 29 Billion Yen in May
Reported Earlier, Daiichi Sankyo And AstraZeneca's ENHERTU Shows Progression-Free Survival To 13.2 Months In HR Positive, HER2 Low Metastatic Breast Cancer
Express News | Reported Monday, Daiichi Sankyo And AstraZeneca's Datopotamab Deruxtecan Show Survival Improvement Versus Chemotherapy In Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer In TROPION-Lung01 Phase 3 Trial
RevolKa Signed Master Service Agreement With Daiichi Sankyo
AstraZeneca and Daiichi Sankyo's ADC Improves Survival in NSCLC Trial
Jefferies Adjusts Daiichi Sankyo's Price Target to 6,600 Yen From 5,600 Yen, Keeps at Buy
Daiichi Sankyo Highlights Progress in Creating New Standards of Care for Patients Across Multiple Cancers at ASCO
IHH Healthcare Unit Submits Claim Brief Against Daiichi Sankyo in Tokyo Court
Sankyo Seiko FY Net Y2.23B Vs Net Y2.21B
Sankyo Frontier Sees FY Net Y5.10B
Sankyo Kasei FY Net Y346.00M Vs Net Y303.00M
Sankyo Co 6417 Sees FY Net Y42.00B
Express News | Daiichi Sankyo And AstraZeneca's Shows Statistically Significant And Clinically Meaningful Improvement In HR+, HER2 Low Breast Cancer: DESTINY-Breast06 Trial Results
Earnings Call Summary | DAIICHI SANKYO COMPANY LIMITED(DSKYF.US) Q4 2023 Earnings Conference
Daiichi Sankyo's Attributable Profit Soars 84% in Fiscal 2024
Daiichi Sankyo 4Q Japan Business Unit Revenue Y106.6B Vs Y101.5B
Daiichi Sankyo Expects FY Global Revenue From Enhertu Y585.4B Vs Y449.2B
Daiichi Sankyo 4Q Net Profit Beat Y10.50B Expected in Poll of Analysts by Visible Alpha
Daiichi Sankyo Raises FY Dividend to Y50.00
Analysis
Price Target
No Data
No Data